Welcome to our dedicated page for Owlet SEC filings (Ticker: OWLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Owlet, Inc. filings document regulatory disclosures for a public pediatric health technology company whose Class A common stock trades on the New York Stock Exchange under OWLT. Recent Form 8-K reports cover operating results, business updates, executive leadership changes, annual meeting matters and stockholder approval of amendments to the company's equity incentive plan.
The filing record also includes disclosures tied to capital structure and financing activity, including preliminary financial information related to an offering and borrowings under an asset-based revolving credit facility. Other material-event filings document shareholder derivative litigation settlement notices, exchange-listed securities, governance matters and exhibits furnished with earnings releases.
Owlet, Inc. (OWLT) launched a primary offering of Class A common stock via a preliminary prospectus supplement on the NYSE. The company plans to grant underwriters a 30‑day option to purchase additional shares, with proceeds to support continued commercialization, research and development, and general corporate purposes.
Owlet reported preliminary Q3 2025 results: revenue of $30–$32 million versus $22.1 million a year ago; gross margin of 49.5%–51% versus 52.2% last year, reflecting tariff impacts on cost of goods sold; and cash and cash equivalents of $23.8 million, including $18.6 million of additional borrowings under its asset‑based revolver. On October 10, 2025, the company issued 5,426,429 shares in a warrant exchange, subject to a 180‑day lockup.
Shares outstanding were 16,258,155 as of June 30, 2025, after giving effect to the warrant exchange. The stock last closed at $8.80 on October 20, 2025.
Owlet, Inc. (OWLT) reported an insider ownership change. On 10/10/2025, a director exchanged 131,195 warrants for 80,235 shares of Class A common stock at a ratio of approximately 0.61 shares per warrant (Transaction Codes: A for shares acquired, D for warrants disposed).
The warrants were initially issued in February 2023 in connection with the Company’s Series A Convertible Preferred Stock. Following the transaction, the director beneficially owns 419,004 shares directly and holds 0 warrants. The warrants carried a $4.44 exercise price; the filing lists a $0 price for the derivative security exchange.
Owlet, Inc. (OWLT): Director Form 4 filing — On 10/10/2025, a director acquired 107,626 shares of Class A common stock. Following the transaction, the director beneficially owns 233,030 shares, held directly.
The shares were issued in exchange for previously held warrants tied to the company’s Series A (February 2023) and Series B (February 2024) preferred financings, at approximate exchange ratios of 0.61 and 0.56 shares per warrant. Two warrant positions for 131,195 and 48,621 underlying shares were disposed, leaving zero derivative securities.
Owlet, Inc. (OWLT): A reporting person acquired 686,469 shares of common stock on October 10, 2025 via an exchange of previously issued warrants and now directly owns 1,567,468 shares.
The transaction exchanged warrants issued in connection with the company’s Series A and Series B financings for common shares at approximate ratios of 0.61 and 0.56 shares per warrant, respectively. Specifically, 712,915 warrants initially issued on 02/17/2023 (expiring 02/17/2028) and 444,601 warrants initially issued on 02/29/2024 (expiring 03/01/2029) were converted (Transaction Code C). Following the exchange, the reported balance of these derivative securities is 0.
Trilogy Equity Partners filed Amendment No. 4 to its Schedule 13D on Owlet, Inc. (Class A Common Stock), reporting beneficial ownership of 2,022,178 shares, or approximately 8.7% of the class.
The reported stake consists of 1,567,468 common shares, plus 158,309 shares issuable upon conversion of Series A Convertible Preferred and 296,401 shares issuable upon conversion of Series B Convertible Preferred, as disclosed. Owlet had 22,788,420 shares outstanding as of October 10, 2025.
Trilogy has sole voting and dispositive power over the reported shares. On October 10, 2025, Trilogy exchanged 712,915 Series A-related warrants and 444,601 Series B-related warrants for common shares at exchange ratios of 0.61 and 0.56 shares per warrant, respectively.
Owlet, Inc. (OWLT) received an amended Schedule 13D (Amendment No. 5) from Eclipse-affiliated funds and Lior Susan, updating beneficial ownership and disclosing a completed warrant-for-share exchange. On October 10, 2025, Eclipse Early Growth Fund I exchanged 5,300,921 Series A Warrants and 1,166,935 Series B Warrants for 3,898,906 Class A shares for no additional consideration.
Reported beneficial holdings include: Eclipse Continuity Fund I at 1,066,472 shares (4.7%), Eclipse Ventures Fund I at 968,694 shares (4.3%), and Eclipse Early Growth Fund I at 7,621,469 shares (30.8%), which includes 1,955,800 shares issuable upon preferred stock conversion. Lior Susan is reported at 9,656,635 shares (40.5%). Percentages reference 22,788,420 Class A shares outstanding as of October 14, 2025.
Owlet, Inc. (OWLT): Eclipse-affiliated holders reported an exchange of previously issued warrants for common stock on October 10, 2025. Eclipse Early Growth Fund I, L.P. acquired 3,898,906 shares of common stock in the exchange, and the related Series A and Series B warrants were disposed.
Following the transactions, 5,665,669 shares were beneficially owned indirectly (per footnote (2)). Other Eclipse-managed funds reported indirect holdings of 968,694 shares (per footnote (3)) and 1,066,472 shares (per footnote (4)). The filing identifies the reporting persons as Director, 10% Owner, and “Director by Deputization.”
The exchange covered warrants originally issued in February 2023 (Series A) and February 2024 (Series B) at approximate exchange ratios of 0.61 and 0.56 shares per warrant, respectively, and is noted as exempt under Rule 16b-3.
Owlet (OWLT): Director and 10% owner reports warrant-for-share exchange. On 10/10/2025, Eclipse Early Growth Fund I, L.P. exchanged previously issued Series A and Series B warrants for 3,898,906 shares of Common Stock, at approximate ratios of 0.61 and 0.56 shares per warrant, respectively. The transaction was reported as exempt under Rule 16b-3.
Following the exchange, indirect beneficial ownership reported includes 5,665,669 shares via Eclipse EGF I, 968,694 shares via Eclipse Ventures Fund I, and 1,066,472 shares via Eclipse Continuity Fund I. The Series A (5,300,291 underlying shares) and Series B (1,166,935 underlying shares) warrant positions were reduced to 0.
Owlet (NYSE: OWLT) reported results of its 2025 annual meeting and completed a warrant exchange. Stockholders approved an amendment to the 2021 Incentive Award Plan to increase shares available for issuance by 375,000 shares, subject to the plan’s existing annual increase mechanics. Stockholders also approved a Charter amendment adding officer exculpation to the extent permitted by Delaware law; the Certificate of Amendment became effective on October 10, 2025.
Stockholders ratified PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2025 and elected three Class I directors. They also approved the issuance of shares related to warrant exchanges. Pursuant to the approved exchanges, holders swapped Series A and Series B warrants relating to an aggregate of 9,014,758 warrant shares (7,215,737 + 1,799,021) for 5,426,429 newly issued shares of common stock. The company consummated the exchanges on October 10, 2025. After giving effect, common shares outstanding were 22,788,420.
Owlet, Inc. reported previously disclosed leadership changes effective October 1, 2025, with Kurt Workman resigning as Chief Executive Officer to become Executive Chair of the Board and Jonathan Harris, formerly President, becoming President and Chief Executive Officer.
In connection with Mr. Workman’s transition, the compensation committee approved full vesting of his unvested restricted stock units, including 7,049 RSUs granted in March 2022 and 88,692 RSUs granted in September 2024, a one-time cash bonus for performance from January 1 through September 30, 2025, and adoption of an amended non-employee director compensation program under which the Executive Chair receives a $200,000 annual cash retainer and is eligible for an annual $200,000 RSU grant. The company also entered into an amended and restated offer letter with Mr. Harris, providing a $500,000 annual base salary, an annual bonus target equal to 70% of salary, and continued Tier 1 change-in-control and severance protections, including 12 months of base-salary continuation and vesting of unvested equity upon certain terminations.